Chapters

Transcript

Video

Why are patients who should clearly be on a PCSK9 inhibitor not being treated in the primary cardiology setting, but rather seeking and obtaining this treatment in the lipid clinic environment?

Why are patients who should clearly be on a PCSK9 inhibitor not being treated in the primary cardiology setting, but rather seeking and obtaining this treatment in the lipid clinic environment?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Anne C. Goldberg, MD, FNLA, FACP, FAHA

Anne C. Goldberg, MD, FNLA, FACP, FAHA

Professor of Medicine
Division of Endocrinology, Metabolism & Lipid Research
Washington University in St. Louis
St. Louis, MO